{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:38:07Z","timestamp":1793284687662,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018592","name":"Celltrion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12325-025-03447-6","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:34:33Z","timestamp":1768822473000},"page":"1016-1033","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult\u00a0Patients with Moderate-to-Severe Crohn\u2019s Disease: A Systematic Literature Review and Network Meta-Analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2254-7771","authenticated-orcid":false,"given":"Stefan","family":"Schreiber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-249X","authenticated-orcid":false,"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-3536","authenticated-orcid":false,"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0972-8148","authenticated-orcid":false,"given":"Peter M.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6397-9597","authenticated-orcid":false,"given":"Hyunsoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-2432","authenticated-orcid":false,"given":"Dong-Hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2776-4708","authenticated-orcid":false,"given":"Young Nam","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3268-932X","authenticated-orcid":false,"given":"Stephen B.","family":"Hanauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"3447_CR1","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1053\/j.gastro.2021.04.023","volume":"160","author":"S Singh","year":"2021","unstructured":"Singh S, Proctor D, Scott FI, et al. AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease. Gastroenterology. 2021;160:2512-556.e9.","journal-title":"Gastroenterology"},{"key":"3447_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/ajg.2016.524","volume":"112","author":"SF Jeuring","year":"2017","unstructured":"Jeuring SF, van den Heuvel TR, Liu LY, et al. Improvements in the long-term outcome of Crohn\u2019s disease over the past two decades and the relation to changes in medical management: results from the population-based IBDSL cohort. Am J Gastroenterol. 2017;112:325\u201336.","journal-title":"Am J Gastroenterol"},{"key":"3447_CR3","unstructured":"US Food and Drug Administration. Remicade (infliximab) highlights of prescribing information. 1998. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/103772s5389s5391s5394lbl.pdf. Accessed 10 June 2025."},{"key":"3447_CR4","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","volume":"160","author":"JD Feuerstein","year":"2021","unstructured":"Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease. Gastroenterology. 2021;160:2496\u2013508.","journal-title":"Gastroenterology"},{"key":"3447_CR5","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3390\/ph16091272","volume":"16","author":"M Imbrizi","year":"2023","unstructured":"Imbrizi M, Magro F, Coy CSR. Pharmacological therapy in inflammatory bowel diseases: a narrative review of the past 90\u00a0years. Pharmaceuticals (Basel). 2023;16:1272.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3447_CR6","unstructured":"European Medicines Agency. Remsima summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remsima-epar-product-information_en.pdf. Accessed 10 June 2025."},{"key":"3447_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247657","volume":"12","author":"A Kubesch","year":"2023","unstructured":"Kubesch A, Kruse N, Jungheim F, et al. Switching vedolizumab from IV to SC injection in inflammatory bowel disease patients with active disease: real-world experience from a German IBD cohort. J Clin Med. 2023;12:7657.","journal-title":"J Clin Med"},{"key":"3447_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2020;14:4\u201322.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"3447_CR9","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","volume":"120","author":"GR Lichtenstein","year":"2025","unstructured":"Lichtenstein GR, Loftus EV, Afzali A, et al. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2025;120(6):1225\u201364.","journal-title":"Am J Gastroenterol"},{"key":"3447_CR10","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","volume":"18","author":"H Gordon","year":"2024","unstructured":"Gordon H, Minozzi S, Kopylov U, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2024;18:1531\u201355.","journal-title":"J Crohns Colitis"},{"key":"3447_CR11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/MEG.0000000000002552","volume":"35","author":"JK Chahal","year":"2023","unstructured":"Chahal JK, Sriranganathan D, Poo S, et al. Network meta-analysis: efficacy and safety of treatments for fistulising Crohn\u2019s disease. Eur J Gastroenterol Hepatol. 2023;35:702\u201310.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3447_CR12","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1007\/s10620-023-08252-1","volume":"69","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Bossuyt P, Bettenworth D, et al. Comparative efficacy of subcutaneous and intravenous infliximab and vedolizumab for maintenance treatment of TNF-naive adult patients with inflammatory bowel disease: a systematic literature review and network meta-analysis. Dig Dis Sci. 2024;69:1808\u201325.","journal-title":"Dig Dis Sci"},{"key":"3447_CR13","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.cgh.2023.12.023","volume":"22","author":"SK Vuyyuru","year":"2024","unstructured":"Vuyyuru SK, Nguyen TM, Murad MH, et al. Comparative efficacy of advanced therapies for achieving endoscopic outcomes in Crohn\u2019s disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2024;22:1190\u20131199.e15.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3447_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/apt.18110","volume":"60","author":"M Attauabi","year":"2024","unstructured":"Attauabi M, Steenholdt C, Poulsen A, et al. Network meta-analysis: comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn\u2019s disease. Aliment Pharmacol Ther. 2024;60:124\u201343.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3447_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/bmjebm-2017-110887","volume":"23","author":"EG Faltinsen","year":"2018","unstructured":"Faltinsen EG, Storeb\u00f8 OJ, Jakobsen JC, et al. Network meta-analysis: the highest level of medical evidence? BMJ Evid Based Med. 2018;23(2):56\u20139.","journal-title":"BMJ Evid Based Med"},{"key":"3447_CR16","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570\u201383.","journal-title":"Gastroenterology"},{"key":"3447_CR17","unstructured":"Park H, Kim D-H. CRD42023413752: Network meta-analysis to evaluate the comparative efficacy of advanced therapies for maintenance treatment of patients with Crohn\u2019s disease. 25 Sep 2023. https:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?RecordID=413752. Accessed 10 June 2025."},{"key":"3447_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"3447_CR19","unstructured":"Higgins JPT, Savovi\u0107 J, Page MJ, et al. Chapter 8: assessing risk of bias in a randomized trial. In: Higgins JPT, et al., editor. Cochrane Handbook for Systematic Reviews of Interventions Version 64. Cochrane; 2023."},{"key":"3447_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G Rucker","year":"2015","unstructured":"Rucker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58.","journal-title":"BMC Med Res Methodol"},{"key":"3447_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12874-021-01381-z","volume":"21","author":"TH Barker","year":"2021","unstructured":"Barker TH, Migliavaca CB, Stein C, et al. Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence. BMC Med Res Methodol. 2021;21:189.","journal-title":"BMC Med Res Methodol"},{"key":"3447_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac190.0126","volume":"17","author":"JF Colombel","year":"2023","unstructured":"Colombel JF, Hanauer SB, Sandborn W, et al. DOP86 subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn\u2019s disease: a phase\u00a03, randomised, placebo-controlled study (LIBERTY-CD). J Crohns Colitis. 2023;17:i161\u20132.","journal-title":"J Crohns Colitis"},{"key":"3447_CR23","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","volume":"167","author":"SB Hanauer","year":"2024","unstructured":"Hanauer SB, Sands BE, Schreiber S, et al. Subcutaneous infliximab (CT-P13) as maintenance therapy for inflammatory bowel disease: 2 randomized phase\u00a03 trials. Gastroenterology. 2024;167:919\u201333.","journal-title":"Gastroenterology"},{"key":"3447_CR24","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT\u00a0I randomised trial. Lancet. 2002;359:1541\u20139.","journal-title":"Lancet"},{"key":"3447_CR25","unstructured":"European Medicines Agency. Remicade summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_en.pdf. Accessed 5 Nov 2024."},{"key":"3447_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369:711\u201321.","journal-title":"N Engl J Med"},{"key":"3447_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","volume":"23","author":"BE Sands","year":"2017","unstructured":"Sands BE, Sandborn WJ, Van Assche G, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease in patients na\u00efve to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis. 2017;23:97\u2013106.","journal-title":"Inflamm Bowel Dis"},{"key":"3447_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","volume":"16","author":"S Vermeire","year":"2022","unstructured":"Vermeire S, D\u2019Haens G, Baert F, et al. Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn\u2019s disease: results from the VISIBLE2 randomised trial. J Crohns Colitis. 2022;16:27\u201338.","journal-title":"J Crohns Colitis"},{"key":"3447_CR29","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375:1946\u201360.","journal-title":"N Engl J Med"},{"key":"3447_CR30","unstructured":"Janssen Biotech, Inc. Stelara\u00ae: Fast. 2023. https:\/\/www.stelarahcp.com\/crohns-disease\/efficacy\/. Accessed 5 Nov 2024."},{"key":"3447_CR31","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","volume":"20","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, Rebuck R, Wang Y, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn\u2019s disease: the IM-UNITI trial. Clin Gastroenterol Hepatol. 2022;20:578\u201390.e4.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3447_CR32","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1053\/j.gastro.2018.06.035","volume":"155","author":"P Rutgeerts","year":"2018","unstructured":"Rutgeerts P, Gasink C, Chan D, et al. Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn\u2019s disease. Gastroenterology. 2018;155:1045\u201358.","journal-title":"Gastroenterology"},{"key":"3447_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132:52\u201365.","journal-title":"Gastroenterology"},{"key":"3447_CR34","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","volume":"399","author":"M Ferrante","year":"2022","unstructured":"Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase\u00a03 FORTIFY maintenance trial. Lancet. 2022;399:2031\u201346.","journal-title":"Lancet"},{"key":"3447_CR35","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, Panes J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2023;388:1966\u201380.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"3447_CR36","doi-asserted-by":"publisher","first-page":"i759","DOI":"10.1093\/ecco-jcc\/jjac190.0760","volume":"17","author":"SW Schreiber","year":"2023","unstructured":"Schreiber SW, Lim A, Lacerda AP, et al. P630 Upadacitinib improves clinical outcomes in patients with moderate to severely active Crohn\u2019s disease irrespective of previous failure to respond to biologics or conventional therapies. J Crohns Colitis. 2023;17(Suppl 1):i759\u201362.","journal-title":"J Crohns Colitis"},{"issue":"Suppl 1","key":"3447_CR37","doi-asserted-by":"publisher","first-page":"i22","DOI":"10.1093\/ecco-jcc\/jjac190.0017","volume":"17","author":"BG Feagan","year":"2023","unstructured":"Feagan BG, Horst S, Dryden G, et al. OP17 Upadacitinib improves endoscopic outcomes in patients with moderate to severely active Crohn\u2019s disease irrespective of previous failure to respond to biologics or conventional therapies. J Crohns Colitis. 2023;17(Suppl 1):i22\u20135.","journal-title":"J Crohns Colitis"},{"key":"3447_CR38","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","volume":"399","author":"BE Sands","year":"2022","unstructured":"Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase\u00a03b trial. Lancet. 2022;399:2200\u201311.","journal-title":"Lancet"},{"key":"3447_CR39","doi-asserted-by":"publisher","first-page":"1057b","DOI":"10.1016\/S0016-5085(24)05019-4","volume":"166","author":"R Panaccione","year":"2024","unstructured":"Panaccione R, Danese S, Feagan BG, et al. Efficacy and safety of guselkumab therapy in patients with moderately to severely active Crohn\u2019s disease: results of the Galaxi 2 & 3 phase\u00a03 studies. Gastroenterology. 2024;166:1057b-b2.","journal-title":"Gastroenterology"},{"key":"3447_CR40","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","volume":"404","author":"M Ferrante","year":"2024","unstructured":"Ferrante M, D\u2019Haens G, Jairath V, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase\u00a03, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet. 2024;404:2423\u201336.","journal-title":"Lancet"},{"key":"3447_CR41","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","volume":"72","author":"B Barberio","year":"2023","unstructured":"Barberio B, Gracie DJ, Black CJ, et al. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn\u2019s disease: systematic review and network meta-analysis. Gut. 2023;72:264\u201374.","journal-title":"Gut"},{"key":"3447_CR42","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/apt.14852","volume":"48","author":"S Singh","year":"2018","unstructured":"Singh S, Fumery M, Sandborn WJ, et al. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn\u2019s disease. Aliment Pharmacol Ther. 2018;48:394\u2013409.","journal-title":"Aliment Pharmacol Ther"},{"key":"3447_CR43","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","volume":"6","author":"S Singh","year":"2021","unstructured":"Singh S, Murad MH, Fumery M, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:1002\u201314.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12S","key":"3447_CR44","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.14309\/01.ajg.0000995740.88073.c5","volume":"118","author":"L Peyrin-Biroulet","year":"2023","unstructured":"Peyrin-Biroulet L, Chapman C, Colombel J-F, et al. Risankizumab versus ustekinumab in patients with moderate to severe Crohn\u2019s disease: results from the Phase\u00a03B SEQUENCE trial. Am J Gastroenterol. 2023;118(12S):S1.","journal-title":"Am J Gastroenterol"},{"key":"3447_CR45","unstructured":"ClinicalTrials.gov. NCT03926130: A study of mirikizumab (LY3074828) in participants with Crohn\u2019s disease (VIVID-1). 2023. https:\/\/clinicaltrials.gov\/study\/NCT03926130. Accessed 10 June 2025."},{"key":"3447_CR46","unstructured":"ClinicalTrials.gov. NCT03466411: A study of the efficacy and safety of guselkumab in participants with moderately to severely active Crohn\u2019s disease (GALAXI). 2024. https:\/\/clinicaltrials.gov\/study\/NCT03466411. Accessed 10 June 2025."},{"issue":"2","key":"3447_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1136\/gut.35.2.231","volume":"35","author":"C Cellier","year":"1994","unstructured":"Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn\u2019s disease. A prospective multicentre study of 121 cases. The Groupe d\u2019Etudes Th\u00e9rapeutiques des Affections Inflammatoires Digestives. Gut. 1994;35(2):231\u20135.","journal-title":"Gut"},{"issue":"1","key":"3447_CR48","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/gut.27.1.92","volume":"27","author":"P Gomes","year":"1986","unstructured":"Gomes P, du Boulay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut. 1986;27(1):92\u20135.","journal-title":"Gut"},{"key":"3447_CR49","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2065383","volume":"2020","author":"S Dragasevic","year":"2020","unstructured":"Dragasevic S, Sokic-Milutinovic A, Stojkovic Lalosevic M, et al. Correlation of patient-reported outcome (PRO-2) with endoscopic and histological features in ulcerative colitis and Crohn\u2019s disease patients. Gastroenterol Res Pract. 2020;2020:2065383.","journal-title":"Gastroenterol Res Pract"},{"key":"3447_CR50","doi-asserted-by":"publisher","first-page":"943","DOI":"10.18549\/PharmPract.2017.01.943","volume":"15","author":"FS Tonin","year":"2017","unstructured":"Tonin FS, Rotta I, Mendes AM, et al. Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract (Granada). 2017;15:943.","journal-title":"Pharm Pract (Granada)"},{"key":"3447_CR51","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0272989X08330120","volume":"29","author":"N Hawkins","year":"2009","unstructured":"Hawkins N, Scott DA, Woods B. How far do you go? Efficient searching for indirect evidence. Med Decis Making. 2009;29:273\u201381.","journal-title":"Med Decis Making"},{"key":"3447_CR52","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/2229-3485.140550","volume":"5","author":"N Bhatnagar","year":"2014","unstructured":"Bhatnagar N, Lakshmi PV, Jeyashree K. Multiple treatment and indirect treatment comparisons: an overview of network meta-analysis. Perspect Clin Res. 2014;5:154\u20138.","journal-title":"Perspect Clin Res"},{"key":"3447_CR53","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2. Value Health. 2011;14:429\u201337.","journal-title":"Value Health"},{"key":"3447_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099682","volume":"9","author":"G Salanti","year":"2014","unstructured":"Salanti G, Del Giovane C, Chaimani A, et al. Evaluating the quality of evidence from a network meta-analysis. PLOS One. 2014;9:e99682.","journal-title":"PLOS One"},{"issue":"3","key":"3447_CR55","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/jrsm.1397","volume":"11","author":"SE Seide","year":"2020","unstructured":"Seide SE, Jensen K, Kieser M. A comparison of Bayesian and frequentist methods in random-effects network meta-analysis of binary data. Res Synth Methods. 2020;11(3):363\u201378.","journal-title":"Res Synth Methods"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03447-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03447-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03447-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:13:30Z","timestamp":1773825210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03447-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3447"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03447-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stefan Schreiber\u2014advisory committee\/board member for AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Gilead, IMAB, Janssen, Lilly, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Sandoz\/Hexal, Takeda, Theravance, and UCB; lecturer for Hikma; and stockholder of CONARIS AG. Silvio Danese\u2014consultant fees from AbbVie, Alimentiv, Allergan, Amgen, Applied Molecular Transport, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Enthera, Ferring Pharmaceuticals, Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, Lilly, Morphic, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, Teladoc Health, TiGenix, UCB, Vial, and Vifor; and lecture fees from AbbVie, Amgen, Ferring Pharmaceuticals, Gilead, Janssen, Mylan, Pfizer, and Takeda. Jean-Fr\u00e9d\u00e9ric Colombel\u2014research grants from AbbVie, Bristol Myers Squibb, Janssen, Prometheus, and Takeda; lecture fees from AbbVie and Takeda; and consultant fees from AbbVie, Allergan, Amgen, AnaptysBio, Arena Pharmaceuticals, Astellas, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Envision Pharma, Ferring Pharmaceuticals, Galmed Research, Genentech (Roche), GlaxoSmithKline, Immunic, Iterative Scopes, Janssen, Kaleido Biosciences, Landos, Lilly, Merck, Microba Life Science, Novartis, Otsuka Pharmaceutical, Pfizer, Protagonist Therapeutics, Sanofi, Sun, Takeda, TiGenix, and Vifor; and stock options with Intestinal Biotech Development. Tadakazu Hisamatsu\u2014grant support from AbbVie, Boston Scientific, EA Pharma, JIMRO, Kissei, Kyorin, Mitsubishi Tanabe, Mochida, Nippon Kayaku, Pfizer, Takeda, and Zeria; consultant fees from AbbVie, Abivax, Bristol Myers Squibb, EA Pharma, Gilead, Janssen, Lilly, Mitsubishi Tanabe, and Pfizer; and lecture fees from AbbVie, EA Pharma, Janssen, JIMRO, Kissei, Kyorin, Mitsubishi Tanabe, Mochida, Pfizer, and Takeda. Peter M. Irving\u2014lecture fees from AbbVie, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Ferring Pharmaceuticals, Galapagos, Gilead, Janssen, Lilly, MSD, Pfizer, Sandoz, Sapphire Medical, Shire, Takeda, Tillotts, and Warner Chilcott; financial support for research from Celltrion, Galapagos, MSD, Pfizer, and Takeda; and advisory fees from AbbVie, Arena Pharmaceuticals, Boomerang Medical, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Prometheus, Roche, Samsung Bioepis, Sandoz, Takeda, TopiVert, VH2, Vifor Pharma, and Warner Chilcott. Hyunsoo Park\u2014employee of Celltrion Inc. Dong-Hyeon Kim and Young Nam Lee\u2014employees and stockholders of Celltrion Inc. Stephen B. Hanauer\u2014consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Fresenius Kabi, Genentech, Gilead, GSK, Immunic, Janssen, Lilly, Merck, Novartis, Organon, Pfizer, Progenity, Prometheus, Protagonist, Receptos, Salix, Samsung Bioepis, Seres Therapeutics, Takeda, UCB, and VHsquared; clinical research fees from AbbVie, Amgen, Genentech, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer, Prometheus, Receptos, Seres Therapeutics, Takeda, and UCB; speaker for AbbVie, Janssen, Pfizer, and Takeda; review panel member for Intercept Pharmaceuticals; and member of Data Safety Monitoring Boards for Boehringer Ingelheim, Bristol Myers Squibb, Gossamer, Protagonist, and Ventyx.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new data from human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}